Analyst Price Targets — NRIX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 10:43 am | Joseph Catanzaro | Mizuho Securities | $34.00 | $23.06 | StreetInsider | Nurix (NRIX) PT Raised to $34 at Mizuho |
| July 10, 2026 12:43 pm | — | RBC Capital | $33.00 | $22.33 | TheFly | Nurix Therapeutics price target raised to $33 from $30 at RBC Capital |
| July 10, 2026 12:41 pm | Gregory Renza | Truist Financial | $34.00 | $23.05 | TheFly | Nurix Therapeutics price target raised to $34 from $32 at Truist |
| July 10, 2026 11:15 am | — | Stifel Nicolaus | $40.00 | $24.69 | TheFly | Nurix Therapeutics price target raised to $40 from $34 at Stifel |
| July 10, 2026 10:50 am | — | H.C. Wainwright | $34.00 | $24.69 | StreetInsider | Nurix (NRIX) PT Raised to $34 at H.C. WainwrightMember Login |
| June 18, 2026 10:24 am | — | Robert W. Baird | $33.00 | $17.12 | TheFly | Nurix Therapeutics price target raised to $33 from $26 at Baird |
| June 9, 2026 1:30 pm | David Dai | UBS | $23.00 | $15.07 | StreetInsider | UBS Reiterates Buy Rating on Nurix (NRIX) |
| June 9, 2026 11:19 am | Jeet Mukherjee | BTIG | $32.00 | $15.64 | TheFly | Nurix Therapeutics price target raised to $32 from $30 at BTIG |
| June 8, 2026 5:59 pm | — | Truist Financial | $32.00 | $15.64 | TheFly | Nurix Therapeutics price target raised to $32 from $30 at Truist |
| June 8, 2026 5:25 pm | Roger Song | Jefferies | $45.00 | $15.56 | TheFly | Nurix Therapeutics price target raised to $45 from $41 at Jefferies |
Latest News for NRIX
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $0.52 per share a year ago.
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NRIX.
U.S. House Trading
No House trades found for NRIX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.